Business model

From 2000 onwards MolMed has evolved into a biopharmaceutical development company, with a primary focus on novel cancer therapies. Today, MolMed is a mature company covering all functions, from discovery  to proof of clinical activity.

MolMed’s strategy for growth is based on four key points:

  • focus on oncology indications that require new therapy options
  • efficiency improvement of clinical and pharmaceutical development, independently or with partners.
  • in-house GMP-based manufacturing of cell and gene therapy products
  • diversified product portfolio to create value.

MolMed is located in Milan, Italy, in the San Raffaele Biomedical Science Park, which houses the renowned San Raffaele research hospital, scientific institute and a private university.

This location offers crucial advantages, allowing MolMed to complement its own R&D resources with the cutting-edge scientific, technological and clinical resources of its host institution, also through its option right on research results of the Scientific Institute in the field of oncology and AIDS.

MolMed S.p.A. Via Olgettina, 58 - 20132 Milano, Italy | Phone +39 0221277.1 - Fax +39 02 21277.325 | -
Privacy & Cookie Policy | Suppliers' Privacy Policy | Customers' Privacy Policy
Share capital € 21,819,020.83 fully paid - Office of Milan Company Registry number 1506630 - Tax identification number 11887610159